Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other financing activities (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Other financing activities for 6 consecutive years, with $102000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities rose 54.55% to $102000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $624000.0 through Dec 2025, up 845.45% year-over-year, with the annual reading at $624000.0 for FY2025, 845.45% up from the prior year.
  • Other financing activities for Q4 2025 was $102000.0 at Cartesian Therapeutics, up from $43000.0 in the prior quarter.
  • The five-year high for Other financing activities was $454000.0 in Q1 2025, with the low at $25000.0 in Q2 2025.
  • Average Other financing activities over 3 years is $133333.3, with a median of $84000.0 recorded in 2024.
  • Peak annual rise in Other financing activities hit 54.55% in 2025, while the deepest fall reached 54.55% in 2025.
  • Over 3 years, Other financing activities stood at $110000.0 in 2022, then plummeted by 40.0% to $66000.0 in 2024, then soared by 54.55% to $102000.0 in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at $102000.0, $43000.0, and $25000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.